Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a Tertiary Care Facility Increases HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Concordance and Decreases the Number of Inconclusive Cases

被引:7
作者
Middleton, Lavinia P. [1 ]
Price, Kathy M. [2 ]
Puig, Pamela [1 ]
Heydon, Lori J. [3 ]
Tarco, Emily [1 ]
Sneige, Nour [1 ]
Barr, Kaye [1 ]
Deavers, Michael T. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Performance Improvement, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Lab Informat, Houston, TX 77030 USA
关键词
METASTATIC BREAST-CANCER; MONOCLONAL-ANTIBODY; AMPLIFICATION; CHEMOTHERAPY; EFFICACY; SAFETY;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline recommendations from January 2007 identified many sources of immunohistochemistry (IHC) testing variation. Objective.-In this current study, we implemented the guidelines and addressed our institution's preanalytic, analytic, and postanalytic variables relating to HER2 testing to improve clinical outcomes. Design.-We evaluated core biopsies performed on breast lesions from 2006 through 2007. Prognostic/predictive markers obtained by IHC were correlated with HER2 fluorescence in situ hybridization (FISH). Preanalytic sources of biopsy testing variation were studied by collecting data on the number of biopsies that needed repeat testing because of inconclusive FISH results. Results.-In the year preceding implementation of the guidelines, the HER2 IHC and FISH concordance was 98%. In an additional 10.8% of cases, the FISH results were in-conclusive. When additional material became available to retest the inconclusive cases, the results were informative. Further evaluation of the inconclusive cases revealed that the core needle biopsies received, on average, 4 hours of formalin fixation. After implementation of a minimum 6 hours of fixation and the ASCO/CAP guideline recommendations, the HER2 IHC and FISH concordance was 98.5%. The number of FISH inconclusive cases decreased from 10.8% to 3.4% (a 64% reduction). Repeat estrogen-receptor IHC requests decreased by 40% from 38 in 2006 to 23 in 2007. Conclusions.-We have shown that standardized fixation and adherence to the ASCO/CAP guidelines for HER2 testing has resulted in a greater HER2 IHC and HER2 FISH correlation, decreased numbers of inconclusive FISH cases, decreased repeat estrogen-receptor requests, and financial savings to the Department of Pathology. (Arch Pathol Lab Med. 2009; 133: 775-780)
引用
收藏
页码:775 / 780
页数:6
相关论文
共 14 条
[1]   Statistical process control as a tool for research and healthcare improvement [J].
Benneyan, JC ;
Lloyd, RC ;
Plsek, PE .
QUALITY & SAFETY IN HEALTH CARE, 2003, 12 (06) :458-464
[2]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648
[3]   Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma [J].
Goldstein, NS ;
Ferkowicz, M ;
Odish, E ;
Mani, A ;
Hastah, F .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 120 (01) :86-92
[4]   HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma [J].
Hoang, MP ;
Sahin, AA ;
Ordòñez, NG ;
Sneige, N .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 113 (06) :852-859
[5]  
Lombardo JF, 2007, ARCH PATHOL LAB MED, V131, P1510
[6]  
Owens Marilyn A, 2004, Clin Breast Cancer, V5, P63, DOI 10.3816/CBC.2004.n.011
[7]   Real-world performance of HER2 testing - National surgical adjuvant breast and bowel project experience [J].
Paik, S ;
Bryant, J ;
Tan-Chiu, E ;
Romond, E ;
Hiller, W ;
Park, K ;
Brown, A ;
Yothers, G ;
Anderson, S ;
Smith, R ;
Wickerham, DL ;
Wolmark, N .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (11) :852-854
[8]   Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831 [J].
Roche, PC ;
Suman, VJ ;
Jenkins, RB ;
Davidson, NE ;
Martino, S ;
Kaufman, PA ;
Addo, FK ;
Murphy, B ;
Ingle, JN ;
Perez, EA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (11) :855-857
[9]   Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].
Slamon, DJ ;
Leyland-Jones, B ;
Shak, S ;
Fuchs, H ;
Paton, V ;
Bajamonde, A ;
Fleming, T ;
Eiermann, W ;
Wolter, J ;
Pegram, M ;
Baselga, J ;
Norton, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792
[10]   HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE [J].
SLAMON, DJ ;
CLARK, GM ;
WONG, SG ;
LEVIN, WJ ;
ULLRICH, A ;
MCGUIRE, WL .
SCIENCE, 1987, 235 (4785) :177-182